Plotting a Path for Tissue ReconstructionPlotting a Path for Tissue Reconstruction

Tissium's co-founder and Chief Innovation Officer, Maria Pereira chronicles her journey into healthcare and how a plan to mend heart tissue led to the formation of a company.

Omar Ford

January 29, 2023

1 Min Read
IMG_2023-1-29-182752.jpg
Image courtesy of Tissium

Tissium was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. The company has made tremendous strides since it began. 

Currently, the Company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products.

Tissium's co-founder and Chief Innovation Officer, Maria Pereira spoke to Let's Talk Medtech about the company's success and many of the hurdles and challenges it was facing.  You can listen to the conversation below. 

 

 

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like